DK3445767T3 - Makrocykliske mcl1-inhibitorer til behandling af cancer - Google Patents
Makrocykliske mcl1-inhibitorer til behandling af cancer Download PDFInfo
- Publication number
- DK3445767T3 DK3445767T3 DK17720720.6T DK17720720T DK3445767T3 DK 3445767 T3 DK3445767 T3 DK 3445767T3 DK 17720720 T DK17720720 T DK 17720720T DK 3445767 T3 DK3445767 T3 DK 3445767T3
- Authority
- DK
- Denmark
- Prior art keywords
- macrocyclic
- cancer
- treatment
- mcl1 inhibitors
- mcl1
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 0 *CC(C=C)C#N Chemical compound *CC(C=C)C#N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3445767T3 true DK3445767T3 (da) | 2020-05-18 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17720720.6T DK3445767T3 (da) | 2016-04-22 | 2017-04-21 | Makrocykliske mcl1-inhibitorer til behandling af cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (da) |
| EP (1) | EP3445767B1 (da) |
| JP (1) | JP6894449B2 (da) |
| KR (1) | KR102388208B1 (da) |
| CN (1) | CN109071566B (da) |
| AR (1) | AR108301A1 (da) |
| AU (1) | AU2017252222B2 (da) |
| BR (1) | BR112018070677B1 (da) |
| CL (1) | CL2018002410A1 (da) |
| CO (1) | CO2018008759A2 (da) |
| CR (1) | CR20180499A (da) |
| CY (1) | CY1123186T1 (da) |
| DK (1) | DK3445767T3 (da) |
| DO (1) | DOP2018000222A (da) |
| EA (1) | EA036551B1 (da) |
| ES (1) | ES2791319T3 (da) |
| HR (1) | HRP20200673T1 (da) |
| HU (1) | HUE049591T2 (da) |
| IL (1) | IL262237B (da) |
| LT (1) | LT3445767T (da) |
| MA (1) | MA44721B1 (da) |
| ME (1) | ME03729B (da) |
| MX (1) | MX386103B (da) |
| NI (1) | NI201800093A (da) |
| PE (1) | PE20181803A1 (da) |
| PH (1) | PH12018502227A1 (da) |
| PL (1) | PL3445767T3 (da) |
| PT (1) | PT3445767T (da) |
| RS (1) | RS60257B1 (da) |
| SG (1) | SG11201805838UA (da) |
| SI (1) | SI3445767T1 (da) |
| SM (1) | SMT202000249T1 (da) |
| SV (1) | SV2018005742A (da) |
| TN (1) | TN2018000319A1 (da) |
| TW (1) | TWI742074B (da) |
| WO (1) | WO2017182625A1 (da) |
| ZA (1) | ZA201807766B (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| EP3411046B1 (en) | 2016-02-04 | 2025-07-16 | The Johns Hopkins University | Rapaglutins, novel inhibitors of glut and use thereof |
| WO2017136717A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| SMT202000249T1 (it) | 2016-04-22 | 2020-07-08 | Astrazeneca Ab | Inibitori di mcl1 macrociclici per il trattamento di cancro |
| US10981932B2 (en) | 2016-05-19 | 2021-04-20 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| CR20200124A (es) | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| US20190055264A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11286263B2 (en) | 2017-11-17 | 2022-03-29 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives |
| WO2019096905A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| AR113886A1 (es) | 2017-11-17 | 2020-06-24 | Broad Inst Inc | Derivados de indol macrocíclicos |
| TWI810220B (zh) * | 2017-11-17 | 2023-08-01 | 德商拜耳廠股份有限公司 | 經取代之巨環吲哚衍生物 |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| AU2019347963A1 (en) * | 2018-09-30 | 2021-05-27 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| US12319703B2 (en) | 2019-01-23 | 2025-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrazoles as Mcl-1 inhibitors |
| US20220144854A1 (en) * | 2019-03-08 | 2022-05-12 | Zeno Management, Inc. | Macrocyclic compounds |
| CN113924300A (zh) | 2019-04-11 | 2022-01-11 | 百时美施贵宝公司 | 用于达到治疗血浆浓度的增加效能的非晶形固体及经溶解调配物 |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| AU2020273654B2 (en) | 2019-05-10 | 2026-04-09 | Janssen Biotech, Inc. | Macrocyclic chelators and methods of use thereof |
| US12338250B2 (en) | 2019-05-17 | 2025-06-24 | The Broad Institute, Inc. | Methods of preparing macrocyclic indoles |
| CA3138058A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| JP7617861B2 (ja) * | 2019-06-21 | 2025-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の大環状阻害剤 |
| BR112022000251A2 (pt) | 2019-07-09 | 2022-05-17 | Janssen Pharmaceutica Nv | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| MX2022006179A (es) * | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de indol como inhibidores de mcl-1. |
| MX2022006180A (es) * | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |
| US20230192720A1 (en) * | 2019-12-18 | 2023-06-22 | Zeno Management, Inc. | Macrocyclic compounds |
| EP4107161A1 (en) * | 2020-02-21 | 2022-12-28 | Janssen Pharmaceutica NV | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| WO2021197295A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| KR20230017823A (ko) | 2020-05-29 | 2023-02-06 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 7-피라졸-5-일-인돌 유도체 |
| AU2021291056A1 (en) | 2020-06-19 | 2023-02-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| ES2994690T3 (en) * | 2020-06-19 | 2025-01-30 | Janssen Pharmaceutica Nv | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| BR112023000212A2 (pt) | 2020-07-08 | 2023-01-31 | Janssen Pharmaceutica Nv | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| WO2022115451A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| KR20230121807A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 분지형 매크로사이클릭 4-(피라졸-5-일)-인돌유도체 |
| AU2022220818A1 (en) | 2021-02-12 | 2023-09-28 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| EP4413165A1 (en) | 2021-10-06 | 2024-08-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| PE20251072A1 (es) | 2022-05-20 | 2025-04-10 | Novartis Ag | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2705599T3 (es) * | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| US7981888B2 (en) | 2007-04-16 | 2011-07-19 | Abbott Laboratories | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives |
| DK2379580T3 (da) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Hidtil ukendte antibakterielle midler til behandling af gram-positive infektioner |
| US8674115B2 (en) * | 2009-12-23 | 2014-03-18 | Ironwood Pharmaceuticals, Inc. | CRTH2 modulators |
| JP5997763B2 (ja) * | 2011-05-19 | 2016-09-28 | フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ | タンパク質キナーゼ阻害剤としての大環状化合物 |
| WO2014047427A2 (en) | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
| CA2922341C (en) | 2013-08-28 | 2022-06-07 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| ES2654242T3 (es) * | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana |
| JP6757312B2 (ja) | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| CR20160471A (es) * | 2014-04-11 | 2016-12-21 | Bayer Pharma AG | Compuestos novedosos macrocíclicos |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| SMT202000249T1 (it) | 2016-04-22 | 2020-07-08 | Astrazeneca Ab | Inibitori di mcl1 macrociclici per il trattamento di cancro |
-
2017
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| HUE049591T2 (hu) | Makrociklusos MCL-1 inhibitorok rák kezelésére | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3515937T3 (da) | Behandling af refraktorisk migræne | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3122358T3 (da) | Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| IL261047A (en) | Taf1 inhibitors for the therapy of cancer | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer |